Valuation: Arcus Biosciences, Inc.

Market Cap 2.69B 2.42B 2.24B 2.02B 3.83B 252B 3.92B 26.83B 10.69B 135B 10.09B 9.87B 430B P/E 2026 *
-5.29x
P/E 2027 * -5.68x
Enterprise Value 2.12B 1.91B 1.76B 1.59B 3.02B 199B 3.09B 21.14B 8.43B 106B 7.95B 7.78B 339B EV / Sales 2026 *
29.3x
EV / Sales 2027 * 54.6x
Free-Float
74.53%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Arcus Biosciences, Inc.

1 day+0.21%
1 week-3.16%
Current month+2.80%
1 month-23.17%
3 months-34.93%
6 months-24.78%
Current year-21.53%
1 week 17.5
Extreme 17.5
19.42
1 month 17.43
Extreme 17.43
24.73
Current year 17.43
Extreme 17.43
31.74
1 year 17.43
Extreme 17.43
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 2015-04-30
Chief Executive Officer 67 2015-04-30
Director of Finance/CFO 53 2020-07-31
Director TitleAgeSince
Chairman 67 2017-11-30
Director/Board Member 65 2017-09-17
Director/Board Member 72 2015-04-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Exercice

Controller/Auditor

8,481 0.0067%
7/10/26 Sell

Founder

-20,067 0.0160%
6/11/26 Free

Director

22,600 0.0180%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-3.16%-7.84%+39.24% 2.69B
-1.06%+9.92%+59.12%+68.61% 68.32B
+1.30%+7.41%+14.79%+90.26% 60.26B
+0.39%+0.30%+20.04%+97.74% 55.86B
-1.00%+11.14%+22.17%+111.14% 48.43B
+1.10%+5.57%+27.43%+43.79% 45.34B
-5.76%-8.54%+185.02%+829.47% 41.76B
+1.97%+9.00%+25.20%+50.98% 34.5B
-0.56%-0.48%+85.57%+57.71% 33.8B
-1.49%+13.52%+43.09%+0.06% 25.96B
Average -0.47%+3.73%+47.46%+138.90% 42B
Weighted average by Cap. -0.47%+4.00%+50.26%+147.29%

Financials

2026 *2027 *
Net sales 72.4M 65.26M 60.29M 54.5M 103M 6.79B 106M 723M 288M 3.64B 272M 266M 11.57B 46.03M 41.49M 38.33M 34.65M 65.56M 4.32B 67.17M 459M 183M 2.31B 173M 169M 7.36B
Net income -462M -416M -385M -348M -658M -43.33B -674M -4.61B -1.84B -23.2B -1.73B -1.7B -73.84B -437M -394M -364M -329M -622M -40.98B -638M -4.36B -1.74B -21.95B -1.64B -1.6B -69.84B
Net Debt -570M -513M -474M -429M -811M -53.43B -831M -5.69B -2.27B -28.62B -2.14B -2.09B -91.07B -174M -157M -145M -131M -248M -16.31B -254M -1.74B -692M -8.73B -653M -639M -27.79B
Projected Income Statement - Annual - Arcus Biosciences, Inc.
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
26-11-11 $18.75 +0.40% 288,908
26-11-10 $18.67 -1.48% 1,152,276
26-11-09 $18.95 +3.67% 976,099
26-11-06 $18.28 +3.34% 1,055,363
26-11-05 $17.69 -8.39% 2,036,343
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Arcus Biosciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
18.67USD
Average target price
41.00USD
Spread / Average Target
+119.60%
  1. Stock Market
  2. Stocks
  3. RCUS Stock